The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C01 | Cardiac therapy | |
| 3 | C01B | Antiarrhythmics, class I and III | |
| 4 | C01BB | Antiarrhythmics, class Ib | |
| 5 | C01BB01 | Lidocaine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 3 g |
| Active Ingredient | Description | |
|---|---|---|
| Lidocaine |
Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| XYLOCARD Solution for injection | Health Products and Food Branch (CA) | MPI, CA: SPM |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
